Risk factors

Alaunos Therapeutics (TCRT) risk factors

Item 1A of every Alaunos Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open TCRT in Gloomberb →
  • FY2025 10-K risk factors

    42 risks, 18 new, 37 dropped, 11 reworded since the prior year. Alaunos Therapeutics shifted away from broad strategic alternatives to focus entirely on its early preclinical Obesity and Metabolic Disorders Program.

    Filed Mar 31, 2026
  • FY2024 10-K risk factors

    61 risks. Company is evaluating strategic alternatives following a 95% workforce reduction in August 2023. Future depends on finding a strategic transaction or liquidating assets. Licensed TCR-T cell therapies and clinical programs are currently suspended or uncertain.

    Filed Mar 31, 2025